COMMUNIQUÉS West-GlobeNewswire

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

09/10/2024 - 22:15

WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09/10/2024 - 22:05

BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

09/10/2024 - 22:05

SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024

09/10/2024 - 22:04

SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09/10/2024 - 22:01

WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]

Premier Health Announces Notice of Award for Independent Labour for Nordic Customers in Quebec

09/10/2024 - 21:43

MONTRÉAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian healthtech company, announces that it was retained as service [...]

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09/10/2024 - 18:00

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]

Ipsen - Septembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

09/10/2024 - 18:00

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2024

09/10/2024 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2024

09/10/2024 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]

PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study

09/10/2024 - 18:00

A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC) Evaluation of the efficacy of a local treatment with PHAXIAM’s anti- S. aureus [...]

PHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PHAGOSCARPA, sponsorisée par un investigateur

09/10/2024 - 18:00

Étude de phase 2 sponsorisée par l'Assistance Publique – Hôpitaux de Paris (AP-HP) dans le cadre du Programme Hospitalier de Recherche Clinique (PHRC) Évaluation de l'efficacité d'un traitement local avec les phages [...]

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

09/10/2024 - 16:47

PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant [...]

Oncovita appoints Stéphane Altaba as Chief Executive Officer

09/10/2024 - 16:30

Paris, France, October 9 th , 2024 - Oncovita, a biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, today announced the appointment of Dr. Stéphane Altaba as [...]

Health-ISAC Partners with Booz Allen Hamilton to Strengthen Global Cybersecurity in Healthcare

09/10/2024 - 16:22

ORLANDO, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Health-ISAC Partners with Booz Allen Hamilton to Strengthen Global Cybersecurity in Healthcare Health Information Sharing and Analysis Center (Health-ISAC), the non- [...]

USOSM Adds Three Partner Practices to Best-in-Class Network of Oral and Maxillofacial Surgeons

09/10/2024 - 15:40

IRVING, Texas, Oct. 09, 2024 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) has secured new partnerships with three oral and maxillofacial surgeons in three states: California, Alabama and Tennessee. The new [...]

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

09/10/2024 - 15:18

-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: [...]

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

09/10/2024 - 15:15

-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a [...]

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

09/10/2024 - 15:15

Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities BERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Cyclacel [...]